Compare Abeona Therapeutics Inc (ABEO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lufax Holding Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Lufax Holding Ltd trades at $1.39 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 6.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | LU | |
|---|---|---|
Market Cap | $373.32M | $2.41B |
Sector | Health | Technology |
52-Week High | $7.23 | $4.40 |
52-Week Low | $4.17 | $1.23 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
LU trades at $1.42, up 1.43% today, with a bullish technical signal but bearish moving averages. The stock shows deep value with a P/S of 0.36 and P/B of 0.1, yet profitability is weak with a -9.08% net margin and negative ROE. Recent news is dominated by a securities class action lawsuit with a May 20, 2026 deadline, creating significant headline risk.
The outlook is mixed; low valuations and a bullish analyst consensus (61.5% buy ratings) suggest potential upside, but negative earnings, cash flow challenges, and legal overhang present substantial risks. Investor sentiment is cautious due to the litigation, making near-term performance highly dependent on case developments and future earnings delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
